Do the lactotripeptides isoleucine-proline-proline and valine-proline- proline reduce systolic blood pressure in european subjects? a meta-analysis of randomized controlled trials

American Journal of Hypertension

Volumn 26, Issue 3, 2013, Pages 442-449

  Cicero, Arrigo F G ^a   Aubin, Francois ^b   Azais Braesco, Veronique ^c   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Cardinal Systems   (France)

^c VAB nutrition   (France)

Author keywords

blood pressure; hypertension; IPP; meta analysis; VPP

Indexed keywords

ISOLEUCYLPROLYLPROLINE; PLACEBO; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERTENSION; MILK; OLIGOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876557415     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hps044     Document Type: Review

References (39)

1. US Department of Health, Education, and Welfare. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2004;43:1-3v.
2. Pripp AH. Effect of peptides derived from food proteins on blood pressure: a meta-analysis of randomized controlled trials. Food Nutr Res 2008;52:doi: 103402/fnrv52i01641.
3. Xu JY, Qin LQ, Wang PY, Li W, Chang C. Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition 2008;24:933-940.
4. Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens 2011;25:425-436.
5. Nakamura Y, Yamamoto N, Sakai K, Takano T. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci 1995;78:1253-1257.
6. Pina AS, Roque AC. Studies on the molecular recognition between bioactive peptides and angiotensin-converting enzyme. J Mol Recognit 2009;22:162-168.
7. Hirota T, Nonaka A, Matsushita A, Uchida N, Ohki K, Asakura M, Kitakaze M. Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings. Heart Vessels 2011;26:549-556.
8. Yamaguchi N, Kawaguchi K, Yamamoto N. Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. Eur J Pharmacol 2009;620:71-77.
9. Usinger L, Ibsen H, Linneberg A, Azizi M, Flambard B, Jensen LT. Human in vivo study of the renin-angiotensin-aldosterone system and the sympathetic activity after 8 weeks daily intake of fermented milk. Clin Physiol Funct Imaging 2010;30:162-168.
10. Johnson JA. Ethnic differences in cardiovascular drug response. Circulation 2008;118:1383-1393.
11. Arima H, Anderson C, Omae T, Liu L, Tzourio C, Woodward M, Macmahon S, Neal B, Rodgers A, Chalmers J; PROGRESS Collaborative Group. Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. J Hypertens 2010;28:395-400.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
13. van Mierlo LA, Koning MM, van der Zander K, Draijer R. Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies. Am J Clin Nutr 2009;89:617-623.
14. van der Zander K, Jakel M, Bianco V, Koning MM. Fermented lactotripeptides-containing milk lowers daytime blood pressure in high normal-to-mild hypertensive subjects. J Hum Hypertens 2008;22:804-806.
15. R, version 2.13.1 (2011-07-08), Copyright ©2011 The R Foundation for Statistical Computing, ISBN 3-900051-07-0.
16. Viechtbauer W. Conducting meta-analyses in R with the Metafor package. J Statistical Software 2010;36:1-48.
17. Tuomilehto J, Lindström J, Hyyrynen J, Korpela R, Karhunen ML, Mikkola L, Jauhiainen T, Seppo L, Nissinen A. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J Hum Hypertens 2004;18:795-802. (Pubitemid 39530092)
18. Cicero AF, Rosticci M, Veronesi M, Bacchelli S, Strocchi E, Melegari C, Grandi E, Borghi C. Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, doubleblind, crossover clinical trial. J Med Food 2010;13:1363-1368.
19. de Leeuw PW, van der Zander K, Kroon AA, Rennenberg RM, Koning MM. Dose-dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects. Blood Press 2009;18:44-50.
20. Usinger L, Jensen LT, Flambard B, Linneberg A, Ibsen H. The antihypertensive effect of fermented milk in individuals with prehypertension or borderline hypertension. J Hum Hypertens 2010;24:678-683.
21. Engberink MF, Schouten EG, Kok FJ, van Mierlo LA, Brouwer IA, Geleijnse JM. Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial. Hypertension 2008;51:399-405. (Pubitemid 351159956)
22. Cochran WO. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
23. Begg CB, Mazumbdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
24. Seppo L, Kerojoki O, Suomalainen T, Korpela R. The effect of Lactobacillus helveticus LBK-16H fermented milk on hypertension-a pilot study on humans. Milchwissenschaft 2002;57:124-127. (Pubitemid 34881652)
25. van der Zander K, Bots ML, Bak AA, Koning MM, de Leeuw PW. Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. Am J Clin Nutr 2008;88: 1697-1702.
26. Turpeinen AM, Ikonen M, Kivimaki AS, Kautiainen H, Vapaatalo H, Korpela R. A spread containing bioactive milk peptides Ile-Pro-Pro and Val-Pro-Pro, and plant sterols has antihypertensive and cholesterollowering effects. Food Funct 2012;3:621-627.
27. Cicero AF, Rosticci M, Gerocarni B, Bacchelli S, Veronesi M, Strocchi E, Borghi C. Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. Hypertens Res 2011;34:1035-1040.
28. Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 2003;77:326-330. (Pubitemid 36133373)
29. Turpeinen A-M, Kumpu M, Rönnback M, Seppo L, Kautiainen H, Jauhiainen T, Vapaatalo H, Korpela R. Antihypertensive and cholesterol-lowering effects of a spread 390containing bioactive peptides IPP and VPP and plant sterols. J Functional Foods 2009;1:260-265.
30. Ueshima H, Ogihara T, Baba S, Tabuchi Y, Mikawa K, Hashizume K, Mandai T, Ozawa H, Kumahara Y, Asakura S. The effect of reduced alcohol consumption on blood pressure: a randomised, controlled, single blind study. J Hum Hypertens 1987;1:113-119. (Pubitemid 18075133)
31. He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004:CD004937.
32. Jurgens G, Graudal NA. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride. Cochrane Database Syst Rev 2003:CD004022.
33. Casiglia E, Tikhonoff V, Pessina AC. Hypertension in the elderly and the very old. Expert Rev Cardiovasc Ther 2009;7:659-665.
34. Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med 2007;357:789-796. (Pubitemid 47295645)
35. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
36. Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH; Investigators. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther 2012;34:552-568, 568.e1-9. Epub 2012 Mar 3.
37. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591-603. (Pubitemid 47247855)
38. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685-1697.
39. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008;26:1487-1496.